Eighty-two patients were entered on the study, of whom 57 had more than 25% lymphoblasts in the bone marrow and/or peripheral blood blasts and were classified as having T leukemia. Twenty-five were designated as having T lymphoma.
There were 27 patients who presented with a medi-astinal mass.
The overall FFS for patients with T leukemia was 27%. FFS for patients with T lymphoma treated was 40%.
Forty-seven of fifty-two successfully completed induction and were randomized to receive or not receive
Was this article helpful?